Clinical Observation of FMD Regimen: Fludarabine, Mitoxantrone, Dexamethasone, in Treatment of

OBJECTIVE To evaluate the clinical eff ectivity and toxicity of the regimen FMD (fl udarabine, mitoxantrone, dexamethasone) in patients with non-Hodgkin’s lymphoma. METHODS Thirty-two patients, twenty-four of whom had indolent B-cell lymphoma, 6 peripheral T-cell lymphoma, two diffuse large B-cell lymphoma, received FMD. Treatment comprised: fludarabine 25~30 mg/m2 days 1~3, mitoxantrone 8~10 mg/m2 day 1, and dexamethasone 20~30 mg /m2 days 1~5. At the same time, patients received prophylaxis against conditional infection with trimethoprim-sulfamethoxazole, fluconazole, acyclovir and immunoglobulin. RESULTS Of the thirty-two patients treated, the complete response (CR) rate, partial response (PR) rate and overall response (OR) rate were 56.3%, 21.9 % and 78.2 % respectively. The CR and OR rate of 24 patients with indolent B-cell lymphoma wer